Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation

Patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who fail first- and second-line treatments face significant challenges in third-line therapy, where monotherapies often yield poor outcomes and limited survival benefits. The prognosis is particularly poor for mCRC with th...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Chunxia He, Jiaxin Chi, Zhihua Du, Zhenjie Zhuang, Liuning Li
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2024-12-01
Seri Bilgileri:	Frontiers in Oncology
Konular:	microsatellite stable (MSS) metastatic colorectal cancer (mCRC) third-line therapy tegafur/gimeracil/oteracil (S-1) fruquintinib sintilimab
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1468532/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!